ClinicalTrials.gg
Status unknownNCT05071651Updated Oct 8, 2021

Epidemiological Characteristics and Prevention Methods of Blisters in Ultra-trail Runners

An observational study in Sport Injury and Blister of Foot, sponsored by Institut de Formation et de Recherche en Médecine de Montagne. Status unknown at 1 site in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-10-08.

Sponsored by Institut de Formation et de Recherche en Médecine de Montagne · Observational

The sponsor has not verified this record recently (last verified Aug 2021), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Study summary

PRIMARY OBJECTIVE : To evaluate the methods of prevention of the appearance of blisters set up by the runners before and during an ultra-trail

SECONDARY OBJECTIVES :

To evaluate :

  • The main locations of blisters.
  • The severity of blisters
  • The effectiveness of prevention methods To evaluate the incidence of blisters in an ultra-trail context.
Read the detailed description

MAIN JUDGEMENT CRITERIA :

Prevention methods used before an ultra-trail via a self-questionnaire

SECONDARY JUDGING CRITERIA : Location of blisters, via a self-questionnaire Presence or not of blisters at the end of the ultra-trail or at the time of abandonment

STUDY SCHEME : Post-race questioning

02

Conditions studied

  • Sport Injury
  • Blister of Foot
03

In context

Athletic Injuries

258 studies on the registry are indexed under Athletic Injuries; 45 are open to participants now.

This study's planned enrollment of 500 is above the median of 100 across 91 observational studies indexed under Athletic Injuries.

Browse Athletic Injuries studies →

Lead sponsor

Institut de Formation et de Recherche en Médecine de Montagne is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

ultra runners

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ultra-trail participants with validated registration

Exclusion criteria

Exclusion Criteria:

  • Presence of blisters or other skin lesions on the feet before the race
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Prevention methods used before an ultra-trail via a self-questionnaire

    Prevention methods used before an ultra-trail

    Time frame: Through study completion, an average of 1 year

Secondary outcomes

  1. Location of blisters, via a self-questionnaire

    Location of blisters on the feet

    Time frame: Through study completion, an average of 1 year

  2. Presence or not of blisters at the end of the ultra-trail or at the time of abandonment

    Presence or not of blisters at the end

    Time frame: Through study completion, an average of 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 8, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05071651
Lead sponsor
Institut de Formation et de Recherche en Médecine de Montagne
Responsible party
Sponsor
First posted
Oct 8, 2021
Start date
Apr 6, 2021
Primary completion
Aug 31, 2021
Completion
Dec 12, 2021 (estimated)
Last update
Oct 8, 2021

Study contacts

Corentin Tanné, MD
Contact
C.Tanne@ch-sallanches-chamonix.fr
0450473105
Corentin Tanné, MD
principal investigator · Institut de Formation et de Recherche en Médecine de Montagne

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion